Inactive Instrument

VectivBio Holding AG

VECT

CH1109007893

VectivBio Holding AG Reports Earnings Results for the Full Year Ended December 31, 2022

April 19, 2023 at 07:05 am EDT

VectivBio Holding AG reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 27.34 million. Net loss was USD 93.74 million compared to USD 87.01 million a year ago.

Basic loss per share from continuing operations was USD 2.12 compared to USD 3.23 a year ago. Diluted loss per share from continuing operations was USD 2.12 compared to USD 3.23 a year ago.

Latest news about VectivBio Holding AG

VectivBio Holding AG(NasdaqGS:VECT) dropped from NASDAQ Composite Index	23-07-07	CI
Sector Update: Health Care Stocks Advancing Late Thursday	23-06-29	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	23-06-29	MT
Ironwood Pharmaceuticals, VectivBio Say Tender Offer for VectivBio Shares Completed	23-06-29	MT
Ironwood Pharmaceuticals, Inc. completed the acquisition of VectivBio Holding AG from Versant Venture Capital V, L.P., managed by Versant Venture Management, LLC, Forbion Growth Opportunities Fund II, managed by Forbion Capital Partners B.V., OrbiMed Advisors LLC and others.	23-06-28	CI
VectivBio Says Takeover by Ironwood Pharmaceuticals Approved at Extraordinary Shareholder Meeting	23-06-26	MT
Ironwood Pharmaceuticals Tender Offer for VectivBio Clears Antitrust Waiting Period	23-06-16	MT
VectivBio Holding Ag Approves Amendments to the Articles of Association	23-06-02	CI
Credit Suisse Downgrades VectivBio Holding to Neutral From Outperform on Heels of Announced Sale to Ironwood Pharmaceuticals, Lowers PT to $17 From $22	23-05-23	MT
Piper Sandler Downgrades VectivBio to Neutral From Overweight, Adjusts Price Target to $17 From $25	23-05-23	MT
SVB Securities Downgrades VectivBio to Market Perform From Outperform, Adjusts Price Target to $17 From $30	23-05-23	MT
Health Care Up Slightly as Pfizer Rallies on Weight-Drug Hopes -- Health Care Roundup	23-05-22	DJ
Ironwood Pharmaceuticals to Buy VectivBio for $1 Billion, Enhancing Gastrointestinal Portfolio	23-05-22	MT
Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy	23-05-22	RE
Ironwood Pharmaceuticals to Acquire Switzerland-Based VectivBio for About $1 Billion	23-05-22	MT
Transcript : Ironwood Pharmaceuticals, Inc., VectivBio Holding AG - M&A Call	23-05-22
Ironwood Pharma To Acquire VectivBio For $1.15 Billion	23-05-22	RE
Ironwood bulks up on digestive therapies with $1.15 bln VectivBio buy	23-05-22	RE
Ironwood Pharma to acquire Swiss-based VectivBio in $1 bln deal	23-05-22	RE
Ironwood Pharmaceuticals, Inc. entered into definitive agreement to acquire VectivBio Holding AG for $1 billion.	23-05-21	CI
Piper Sandler Adjusts VectivBio Price Target to $25 From $23, Maintains Overweight Rating	23-04-20	MT
Transcript : VectivBio Holding AG, 2022 Earnings Call, Apr 19, 2023	23-04-19
VectivBio Reports Narrower Loss for Full-Year 2022	23-04-19	MT
VectivBio Holding AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
VectivBio Holding, Asahi Kasei Pharma Initiate Phase 1 Trial in Japan for Short Bowel Syndrome Treatment	23-03-13	MT

Chart VectivBio Holding AG

Duration

Period

More charts

Company Profile

VectivBio Holding AG is a holding company based in Switzerland. The Company trough it's subsidiaries operates as a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+33.66%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.45%	348B
MERCK & CO., INC.	+18.90%	327B
ABBVIE INC.	+4.62%	288B
ASTRAZENECA PLC	+14.81%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.81%	147B

Other Pharmaceuticals